Press "Enter" to skip to content

Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo | Small Molecules | News Channels – PipelineReview.com

admin 0

Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo | Small Molecules | News Channels  PipelineReview.com
“pancreatic cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *